Appoints Dr.

Appoints Dr. Wolfgang Ruttenstorfer to its Board of Directors

Ziona, July 5, 2018, CollPlant (NASDAQ: CLGN, TASE: CLGN), a regenerative medicine company utilizing its proprietary plant-based

rhCollagen (recombinant human collagen) technology for tissue repair products, today announced the appointment of Dr. Wolfgang

Ruttenstorfer to its board of directors, increasing the board to seven members.

a former board member of Roche Holding AG - one of the world's largest biotechnology company - Wolfgang brings significant

insights and experience that will be invaluable as we continue to execute our strategic vision. Moreover, Wolfgang's notable

finance and strategic planning expertise, garnered during his long tenure at OMV AG, and as Deputy Finance Minister of Austria,

will also serve us well as we grow the business. We are delighted to welcome such a distinguished executive to the CollPlant team,"

noted Yehiel Tal, Chief Executive Officer of CollPlant.

in 1976, Dr. Ruttenstorfer spent a total of approximately 30 years in various capacities with OMV AG, an

integrated oil and gas company headquartered in Vienna, Austria, culminating in his position as chairman of the executive

board from 2002 through mid-2011. From 1997 through 1999, Dr. Ruttenstorfer stepped away from OMV to serve as Deputy Finance

Minister of Austria.

2012, Dr. Ruttenstorfer has been a board member of NIS a.d. Novi Sad, one of the largest, vertically integrated energy companies

in southeast Europe, as well as a member of the supervisory board of RHI AG, a

leading global supplier of high-grade refractory products, systems and services. Since 2011, he has also served as a member of

the supervisory board of Flughafen Wien, AG, the Vienna International Airport. From 2007 through 2011, Dr. Ruttenstorfer lent

his expertise to Roche Holding AG, as a member of the board of directors. During the period from 2009 to early 2018, Dr. Ruttenstorfer

also served at various times on a number of other supervisory boards, including that of CA Immobilien AG, Telekom Austria AG and

Vienna Insurance Group AG. Dr. Ruttenstorfer received his doctorate from the University of Vienna in Economics and Business.

is a regenerative medicine company focused on 3D bioprinting of tissues and organs, developing and commercializing tissue repair

products for orthobiologics, and advanced wound care markets. The Company's products are based on its rhCollagen (recombinant

human collagen) that is produced with its proprietary plant-based genetic engineering technology.

products address indications for diverse fields of organ and tissue repair and are ushering in a new era in regenerative medicine.

The Company's flagship BioInk product line provides an ideal building block for 3D bioprinting of tissues and organs, and

its unique Vergenix line of rhCollagen products includes a soft tissue repair matrix for treating tendinopathy and a wound repair

matrix to promote a rapid optimal healing of acute and chronic wounds.

more information, visit http://www.collplant.com

press release may include forward-looking statements. Forward-looking statements may include, but are not limited to, statements

relating to CollPlant's objectives, plans and strategies, as well as statements, other than historical facts, that address

activities, events or developments that CollPlant intends, expects, projects, believes or anticipates will or may occur in the

future. These statements are often characterized by terminology such as "believes," "hopes," "may,"

"anticipates," "should," "intends," "plans," "will," "expects,"

"estimates," "projects," "positioned," "strategy" and similar expressions and

are based on assumptions and assessments made in light of management's experience and perception of historical trends, current

conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements are not guarantees

of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those

expressed or implied in such statements. Many factors could cause CollPlant's actual activities or results to differ materially

from the activities and results anticipated in forward-looking statements, including, but not limited to, the following: the Company's

history of significant losses and its need to raise additional capital and its inability to obtain additional capital on acceptable

terms, or at all; the Company's expectations regarding the timing and cost of commencing clinical trials with respect to

tissues and organs which are based on its rhCollagen-based BioInk, VergenixSTR, and VergenixFG; the Company's ability to

obtain favorable pre-clinical and clinical trial results; regulatory action with respect to rhCollagen-based BioInk, VergenixSTR,

and VergenixFG, including but not limited to acceptance of an application for marketing authorization, review and approval of

such application, and, if approved, the scope of the approved indication and labeling; commercial success and market acceptance

of the Company's rhCollagen-based BioInk, VergenixSTR, and VergenixFG; the Company's ability to establish sales and

marketing capabilities or enter into agreements with third parties and its reliance on third-party distributors and resellers;

the Company's ability to establish and maintain strategic partnerships and other corporate collaborations; the Company's

reliance on third parties to conduct some aspects of its product manufacturing; the scope of protection we are able to establish

and maintain for intellectual property rights and the Company's ability to operate its business without infringing the intellectual

property rights of others; the overall global economic environment; the impact of competition and new technologies; general market,

political, and economic conditions in the countries in which the Company operates; projected capital expenditures and liquidity;

changes in the Company's strategy; and litigation and regulatory proceedings. More detailed information about the risks

and uncertainties affecting CollPlant is contained under the heading "Risk Factors" included in CollPlant's

most recent annual report on Form 20-F filed with the SEC, and in other filings that CollPlant has made and may make with the

SEC in the future. The forward-looking statements contained in this press release are made as of the date of this press release

and reflect CollPlant's current views with respect to future events, and CollPlant does not undertake and specifically disclaims

any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.